22nd Century Group (XXII) to Announce Quarterly Earnings on Friday

22nd Century Group (NASDAQ:XXII) is anticipated to release its Q2 2026 results before the market opens on Friday, August 14th. Analysts expect the company to announce earnings of ($6.00) per share and revenue of $7.48 million for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 13, 2026 at 8:00 AM ET.

22nd Century Group Stock Down 2.0%

Shares of NASDAQ:XXII opened at $4.31 on Thursday. 22nd Century Group has a 52-week low of $3.61 and a 52-week high of $801.00. The stock has a market cap of $2.24 million, a P/E ratio of -0.00 and a beta of 0.65. The business has a fifty day moving average of $4.98 and a two-hundred day moving average of $46.28. The company has a quick ratio of 2.12, a current ratio of 2.67 and a debt-to-equity ratio of 0.02.

Institutional Investors Weigh In On 22nd Century Group

A hedge fund recently raised its stake in 22nd Century Group stock. Anson Funds Management LP raised its holdings in 22nd Century Group, Inc (NASDAQ:XXII) by 677.1% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 763,212 shares of the biotechnology company’s stock after purchasing an additional 665,000 shares during the quarter. Anson Funds Management LP owned 149.65% of 22nd Century Group worth $588,000 as of its most recent SEC filing. Institutional investors own 18.06% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently weighed in on XXII. Weiss Ratings raised shares of 22nd Century Group from a “sell (e)” rating to a “sell (e+)” rating in a research report on Tuesday, July 28th. Wall Street Zen upgraded shares of 22nd Century Group to a “sell” rating in a research report on Saturday, June 27th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has an average rating of “Sell”.

About 22nd Century Group

22nd Century Group, Inc, founded in 1998 and headquartered in New York, is a plant biotechnology company that applies proprietary breeding and gene modulation technologies to tobacco, hemp and related plant species. The company’s core mission is to develop and commercialize plant-based solutions that address public health, consumer wellness and agronomic needs. Its flagship reduced nicotine tobacco platform is engineered to deliver significantly lower levels of nicotine than conventional tobacco products while retaining the sensory characteristics sought by adult smokers.

Through its branded reduced nicotine tobacco products, marketed under the NEXT Generation™ portfolio, and its GenCanna® subsidiary focused on hemp cultivation and cannabinoid extraction, 22nd Century serves both commercial markets and contract research clients.